Results 71 to 80 of about 10,701 (213)

When psychedelic discourse meets local narrative: Selective uptake of psychedelic meanings surrounding mad honey in Nepal

Addiction, EarlyView.
Abstract Aims ‘Mad honey’ is produced when bees collect nectar from Rhododendron species containing grayanotoxins, naturally occurring diterpenoid toxins that can produce dose‐dependent intoxication. It has long been embedded in Nepalese medicinal and ritual practices but has recently become part of global psychedelic discourse. This study examined how
Sharon R. Sznitman, Surendra Tiwari
wiley   +1 more source

Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention

NeuroImage, 2020
Psychedelic drugs, including the serotonin 2a (5-HT2A) receptor partial agonist psilocybin, are receiving renewed attention for their possible efficacy in treating a variety of neuropsychiatric disorders.
Frederick S. Barrett, Samuel R. Krimmel, Roland R. Griffiths, David A. Seminowicz, Brian N. Mathur   +4 more
doaj   +1 more source

Safety pharmacology of acute mescaline administration in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber, Mélusine Humbert‐Droz, Laura Ley, Yasmin Schmid, Matthias E. Liechti   +4 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Oregon psilocybin business resource guide

, 2023
This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and may not be suitable for legal purposes.Mode of access: Internet from the Oregon Government ...

core  

Structural basis for psilocybin biosynthesis

Nature Communications
Psilocybin shows significant therapeutic potential for psilocybin-assisted psychotherapy in addressing various psychiatric conditions. The biosynthetic approach promises rapid and efficient production of psilocybin.
Chunyan Meng, Wenting Guo, Chuan Xiao, Yan Wen, Xudong Zhu, Qingrong Zhang, Yuxuan Liang, Hongwei Li, Sha Xu, Yuntan Qiu, Haitao Chen, Wei-Jye Lin, Baixing Wu   +12 more
doaj   +1 more source

Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?

Neurobiology of Stress
There is growing interest in exploring the therapeutic potential and mechanisms of action of psilocybin on stress-related neuropsychiatric disorders, including depression, generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD ...
Alanna Kit, Kate Conway, Savannah Makarowski, Grace O'Regan, Josh Allen, Sandy R. Shultz, Tamara S. Bodnar, Brian R. Christie   +7 more
doaj   +1 more source

Cannabis Use Among People Aged 65 and Older: Results From an Intercept Survey in New York City

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Cannabis use among older adults has increased in recent years. Age‐related physiological changes, socio‐ecological factors, and medications may exacerbate potential adverse effects of cannabis and complicate the detection of cannabis use disorder (CUD) in older adults.
Benjamin H. Han, Krish Jagasia, Tyler Simi, Nina Abukahok, Joseph J. Palamar   +4 more
wiley   +1 more source

Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians

Journal of Eating Disorders
Background Clinical trials using psilocybin therapy to treat anorexia nervosa (AN) are currently underway. The safety and tolerability of psilocybin is of utmost importance in individuals with AN who may present unique medical vulnerabilities.
Amanda E. Downey, Anita V. Chaphekar, Joshua Woolley, Marissa Raymond-Flesch   +3 more
doaj   +1 more source

‘So many relationships in the room’: Participant perspectives on the affordances and challenges of co‐therapy in psychedelic assisted therapy

Psychology and Psychotherapy: Theory, Research and Practice, EarlyView.
Abstract Objectives Psychedelic‐assisted therapy (PAT) frequently utilises a “cotherapy” model, in which two therapists jointly support participants throughout dosing and psychotherapy sessions. While common in clinical trials, participant experiences of cotherapy remain underexplored.
Rachel Ham, John Gardner, Adrian Carter, Paul Liknaitzky   +3 more
wiley   +1 more source